The Wistar Institute

University of Pennsylvania

Inovio Pharmaceuticals, Inc.

Kar Muthumani

David B Weiner

Ami Patel

Trevor R F Smith

Jian Yan

Niranjan Y Sardesai

Kate Broderick

Nyamekye Obeng-Adjei

Veronica Scott

Daniel Choo

Makan Khoshnejad

Sagar Kudchodkar

An aspect of the present invention is related to nucleic acid constructs capable of expressing a Zika antigen that elicits an immune response in a mammal against Zika virus, and methods of use thereof. Additionally, there are DNA plasmid vaccines capable of generating in a mammal an immune response against a Zika virus, comprising a DNA plasmid and a pharmaceutically acceptable excipient, and methods of use thereof. The DNA plasmid is capable of expressing a Zika antigen in a cell of the mammal in a quantity effective to elicit an immune response in the mammal that is cross reactive against all Zika strains.

Vaccines against Zika virus

An aspect of the present invention is related to nucleic acid constructs capable of expressing at least one Nipah virus (NiV) antigen that elicits an immune response in a mammal against NiV virus, and methods of use thereof.

Vaccines against Nipah virus, and methods of using same

Nucleic acid molecules and compositions comprising one or more nucleic acid sequences that encode a consensus Crimean-Congo hemorrhagic fever virus (CCHFV) antigens. Immunomodulatory methods and methods of inducing an immune response against CCHFV are disclosed. CCHFV glycoprotein immunogens are disclosed.

DNA vaccine against crimean-congo hemorrhagic fever virus (CCHFV)

Disclosed herein is a composition comprising a nucleic acid sequence encoding a Mayaro Virus antigen that elicits an immune response in a mammal. Also disclosed herein is a nucleic acid sequence encoding an anti-Mayaro Virus antibody, a fragment thereof, a variant thereof. Also disclosed herein is a method of generating a synthetic antibody in a subject by administering the composition to the subject. The disclosure also provides a method of preventing and/or treating a Mayaro virus infection in a subject using said composition and method of generation.

Mayaro virus consensus antigens, DNA antibody constructs for use against Mayaro virus, and combinations thereof

Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody or fragment thereof that targets PCSK9. The disclosure also provides a method of preventing and/or treating disease, such as cardiovascular disease or hypercholesterolemia, in a subject using the composition of the invention.

Nucleic acid monoclonal antibodies targeting PCSK9 and methods of use

Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody to a Middle East Respiratory Syncytial Coronavirus (MERS-CoV) viral antigen. Also disclosed herein is a method of generating a synthetic antibody in a subject by administering the composition to the subject. The disclosure also provides a method of preventing and/or treating an MERS-CoV virus infection in a subject using said composition and method of generation.

DNA antibody constructs for use against middle east respiratory syndrome coronavirus

Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody or fragment thereof that targets an immune checkpoint molecule. The disclosure also provides a method of preventing and/or treating disease in a subject using said composition and method of generation.

DNA monoclonal antibodies targeting checkpoint molecules

Disclosed herein are nucleic acid molecules encoding a SARS-CoV-2 spike antigen, SARS-CoV-2 spike antigens, immunogenic compositions, and vaccines and their use in inducing immune responses and protecting against or treating a Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) infection in a subject.

Vaccines against coronavirus and methods of use

Vaccines against zika virus

Nucleic acid molecules and compositions comprising one or more nucleic acid sequences that encode an RSV immunogen are disclosed. Nucleic acids are disclosed that comprise the sequences that encodes consensus RSV F protein or immuno-genic fragment thereof, sequences that encodes an RSV G(A) protein or immunogenic fragment thereof and sequences that encodes an RSV G(B) protein or immunogenic fragment thereof. Compositions comprising one, combinations of two or all three sequences are disclosed. The coding sequences optionally include operable linked coding sequence that encode a signal peptide. Nucleic acid molecules and compositions comprising the chemokine CC20 and/or a consensus RSV M2-1 protein or immunogenic fragment thereof are also disclosed. Immunomodulatory methods and methods of inducing an immune response against RSV are disclosed. Methods of preventing RSV infection and methods of treating individuals infected with RSV are disclosed.

Growing community of inventors

Cherry Hill, NJ, United States of America

Kar Muthumani